

UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART A - EXPLANATORY NOTES PURSUANT TO MFRS 134

1. BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in accordance with Malaysia Financial Reporting Standard ("MFRS") 134: Interim Financial Reporting and paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of the Group for the financial year ended 31 December 2019. The explanatory notes attached to the interim financial statements provide an explanation of events and transaction that are significant to the understanding of the changes in the financial position and performance of the Group since the financial year ended 31 December 2019.

The audited financial statements of the Group for the year ended 31 December 2019 were prepared in accordance with Malaysian Financial Reporting Standards ("MFRS"). The significant accounting policies and method of computations adopted in preparation of financial report are consistent with those adopted in the audited financial statements of the Group for the financial year ended 31 December 2019.

2. AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The preceding audited financial statements for the year ended 31 December 2019 were no subject to any qualification.

3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE OR INCIDENCE

There were no other unusual items affecting assets, liabilities, equity, net income, and cash flows during the current quarter under review.

4. CHANGES IN ESTIMATES

There were no changes in estimates that have had a material effect in the current quarter results.

5. DEBTS AND EQUITY SECURITIES

There were no issuances, cancellations, repurchases, resale, and repayments of debt and equity securities during the current quarter under review.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

6. DIVIDENDS PAID

There were no dividend paid during current quarter under review.

7. TRADE AND OTHER RECEIVABLES

	As at 30-Sep-20	As at 31-Dec-19
	RM ('000)	RM ('000)
Trade Receivables		
Third parties	31,677	16,932
Allowance for impairment loss	(2,022)	(3,082)
-	29,655	13,850
Other Receivables		-
Third parties and GST receivables	536	15,429
Allowance for impairment loss	(390)	(390)
-	146	15,039
Deposits	272	220
	30,073	29,109

a) Trade Receivables

The Group's normal trade credit term ranges from 30 to 90 days (2019: 30 to 90 days). Other credit terms are assessed and approved on a case-by-case basis. They are recognized at their original invoice amounts which represent their fair value on initial recognition.

The Group recognizes loss allowances for expected credit losses (ELC) on trade receivables measured at amortised cost. The Group applies the simplified approach to provide ECLs for all trade receivables as permitted by MFRS 9. The Group has also elected not to restate the comparatives as permitted by MFRS 9.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

a) Trade Receivables (cont'd)

The following table provides information about the exposure to credit risk and ECLs for trade receivables:

		As at 30-Sep-2	20		As at 31-Dec-1	9
	Gross RM ('000)	Loss Allowance RM ('000)	Net RM ('000)	Gross RM ('000)	Loss Allowance RM ('000)	Net RM ('000)
Not past due	4,432	-	4,432	5,476	-	5,476
Past due:						
- Less than 30 days	2,955	-	2,955	2,051	-	2,051
- 31 to 60 days	1,746	-	1,746	3,164	-	3,164
- 61 to 90 days	3,612	-	3,612	901	(76)	825
- More than 90 days	16,910	-	16,910	2,673	(339)	2,334
	25,223	-	25,523	8,789	(415)	8,374
Credit impaired						
Individually impaired	2,022	(2,022)	-	2,667	(2,667)	-
Trade Receivables, net	31,677	(2,022)	29,655	16,932	(3,082)	13,850

Credit impaired

Trade receivables that are individually determined to be impaired at the reporting date relate to debtors that are in significant financial difficulties and have defaulted payments. These receivables are not secured by any collateral or credit enhancements.

b) Other Receivables

Included in Other Receivables of 31 Dec 2019 is the in-escrow payment from the sale of Electron Beam Sdn Bhd in the amount of RM7.5 million. The terms in the sales and purchase agreement was concluded and the said amount was received on 27 July 2020.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

8. SEGMENTAL INFORMATION

Healthcare: The business involves the supply of healthcare and related products, services to hospitals, healthcare centers and pharmacies. This includes the renal dialysis business which are for home and center-based treatments, serving both the domestic and export markets.

Warehouse & Logistic: Provision of storage, warehousing and logistic services to companies within the Group.

The Group's segmental revenue and profit/(loss) before tax (PBT/LBT) for current quarter are as follow:

Revenue	Individual Quarter Ended		Cumulative Qu	arter Ended
	30-Sep-20	30-Sep-19	30-Sep-20	30-Sep-19
<u>Segment</u>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	15,598	8,442	92,548	18,296
Sterilisation	-	929	-	8,792
Warehouse & logistic	435	262	1,443	717
Corporate	488	786	1,485	786
Elimination	(2,055)	(897)	(20,963)	(1,352)
Total	14,466	9,522	74,513	27,239

PBT/(LBT) result	Individual Qu	arter Ended	Cumulative Qu	arter Ended
	30-Sep-20	30-Sep-19	30-Sep-20	30-Sep-19
<u>Segment</u>	RM ('000)	RM ('000)	RM ('000)	RM ('000)
Healthcare	(5,394)	(2,696)	(2,475)	(4,184)
Sterilization	-	182	-	3,969
Warehouse & logistic	62	(235)	243	(606)
Corporate	105	64,689	(509)	62,690
Elimination	-	(32,508)	-	(32,508)
Total	(5,227)	29,432	(2,741)	29,361

9. VALUATIONS OF PROPERTY, PLANT AND EQUIPMENT

The valuations of property, plant and equipment have been brought forward, without amendment from the previous annual financial statements of the Group.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

10. SIGNIFICANT AND SUBSEQUENT EVENTS

There are no material events subsequent to the end of the reporting period under review that have not been reflected in the quarterly financial statements.

11. CHANGES IN COMPOSITION OF THE GROUP

- On 26 March 2020, Adventa Berhad incorporated PT Humana Medical International in Indonesia with 90% shareholdings. The company became a subsidiary of the Group since the date of incorporation.
- On 30 March 2020, Adventa Berhad incorporated PT Akema Healthcare International in Indonesia with 49% shareholdings. The company became an associate of the Group since the date of incorporation.
- On 5 June 2020, Lucenxia International Sdn Bhd incorporated PT Lucenxia Indonesia International in Indonesia with 70% shareholdings. The Company became a subsidiary of the Group since the date of incorporation.
- On 5 June 2020, Lucenxia International Sdn Bhd acquired 80% equity interest in Lucenxia (Thailand) Co. Ltd for cash consideration of 1,600,000 Thai Baht. Lucenxia (Thailand) Co., Ltd, a company incorporated in Thailand became a subsidiary of the Group
- On 1 November 2020, the directors of the Company has approved the transfer of 100% equity shareholding of Lucenxia International Sdn. Bhd own by Adventa Berhad to Lucenxia (M) Sdn. Bhd. as part of reorganization of the Group structure.

12. CONTINGENT LIABILITIES AND CONTINGENT ASSETS

There were no contingent liabilities or contingent assets for the Group for the current quarter under review.

13. CAPITAL COMMITMENTS

There were no commitments for the purchase of property, plant and equipment at the financial period ended 30 September 2020.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

PART B – ADDITIONAL INFORMATION AS REQUIRED BY APPENDIX 9B OF BURSA MALAYSIA LISTING REQUIREMENTS

14. PERFORMANCE REVIEW

	Individual Quarter Ended 3Q 2020 RM ('000)	Individual Quarter Ended 3Q 2019 RM ('000)	Changes RM ('000)	%
Revenue	14,466	9,522	4,944	52
(Loss)/Profit before tax (LBT/PBT)	(5,227)	29,432*	(3,032)	38
EBITDA	(374)	29,714*	(1,539)	> 100

* Included in PBT of 3Q 2019 is gain on disposal of Electron Beam Sdn. Bhd. (EBSB) of RM31.627m and the loss before tax from operation is RM2.195m. Included in EBITDA of 3Q 2019 is gain on disposal of EBSB of RM31.627m and the EBIDA from operation is (RM1.913m)

The Group achieved a revenue of RM 14.46 million and a loss before tax of RM 5.2 million in Q3 2020. The topline improvement came from healthcare businesses segment, in particular the hospital supplies with personal protective equipment (PPE) being the main contributor. Hospital supplies in other segments are lower due to the dropped in surgeries in hospitals, an impact from the control of movements implemented by the government.

The home dialysis business has stagnated since the implementation of the Movement Controls. It has improved marginally in the third quarter.

The substantial loss in third quarter is substantially due to revaluation of the PPE inventories to net realizable value due to imposition of ceiling price of PPE and the ban on exports of the same.

15. COMPARISON WITH PRECEDING QUARTER'S RESULTS

	Individual Quarter Ended 3Q 2020 RM ('000)	Individual Quarter Ended 2Q 2020 RM ('000)	Changes RM ('000)	%
Revenue	14,466	46,373	(31,907)	(68)
(Loss)/Profit before tax (LBT/PBT)	(5,227)	1,579	(6,806)	>100
EBITDA	(374)	2,402	(2,776)	>100



UNAUDITED NOTES TO FINANCIAL STATEMENTS

15. COMPARISON WITH PRECEDING QUARTER'S RESULTS - Cont'd

Revenue for 3Q 2020 was RM 14.46 million, a 68% drop as compared to 2Q 2020. The drop in revenue is the result of lower selling prices of PPE from various factors, like imposition of ceiling prices by the government and resumption of sufficient supplies from China.

16. COMMENTARY ON CURRENT YEAR PROSPECTS -

With the unabated Covid-19 pandemic and more movement controls in place, we see a weak sales environment till after first quarter 2021, hence the results for the rest of the year will be relatively subdued in all business sectors of the company. Although we are in hospital supplies, but the segments we are in are affected by the pandemic and the reluctance of people to visit hospitals for elective procedures.

17. UTILISATION OF PROCEEDS

The gross proceeds arising from the Electron Beam Sdn Bhd (EBSB) Disposal of RM75 million are as follow.

Details of Utilisation	*Revised Expected utilization time frame	Proposed Utilisation	* Revised Proposed Utilisation	Actual Utilisation	Remaining balance
		RM ('000)	RM ('000)	RM ('000)	RM ('000)
Special dividend	Within 6 months	10,700	10,700	10,700	-
Business expansion	Within 24 months	22,500	6,188	6,188	-
Repayment of bank borrowings	Within 6 months	20,000	20,000	20,000	-
Working capital	Within 12 months	21,000	37,312	32,277	5,035
Estimated expenses	Within 3 months	800	800	800	-
Total		75,000		69,068	5,035

*Announcement on variation to the utilization of consideration from EBSB disposal was made to Bursa Malaysia on 28 August 2020.



UNAUDITED NOTES TO FINANCIAL STATEMENTS

18. PROFIT FORECAST

No profit forecast was announced hence there was no comparison between actual results and forecast.

19. TAXATION

No tax is provided as the company incurred a loss.

		al Quarter ded	Cumulative Quarter Ended	
	30-Sep-20 30-Sep-19		30-Sep-20	30-Sep-19
	RM ('000) RM ('000)		RM ('000)	RM ('000)
Income tax	-	100	-	(348)
Deferred tax	-	585	-	(509)
Total	-	685	-	(857)

20. SALE OF UNQUOTED INVESTMENTS AND PROPERTIES

There was no sale of unquoted investments and properties during the current quarter under review.

21. MARKETABLE SECURITIES

There was no purchase or disposal of marketable securities during the current quarter under review.

22. CORPORATE PROPOSALS

There was no corporate proposal announced which remain uncompleted at the financial period ended 30 September 2020.

22. BANK BORROWINGS AND DEBT SECURITIES

The total bank borrowings of the Group as at financial period ended 30 September 2020 as below.

	As at 30-Sep-20 RM ('000)	As at 31-Dec-19 RM ('000)
Current (Secured):		
Revolving Credit	-	2,500
Term Loan	2,000	2,000
	-	4,500
Non-Current (Secured):		
Term Loan	-	1,500
Total Bank Borrowings	2,000	6,000



UNAUDITED NOTES TO FINANCIAL STATEMENTS

23. CHANGES IN MATERIAL LITIGATION

The Board confirms that the Adventa Group is not engaged in any material litigation, claims or arbitration, either as plaintiff or defendant. The Board has no knowledge of any proceedings pending against Adventa Group or any facts likely to give rise to any proceeding which may have a material impact on the business or the financial position of Adventa Group.

24. EARNINGS PER SHARE

The basic and diluted earnings per share or the reporting period are computed as follows:

a. Basic

	Individual Quarter Ended			ve Quarter ded
	30-Sep-20	30-Sep-19	30-Sep-20	30-Sep-19
Profit attributable to ordinary equity holders of the parent (RM '000)	(5,158)	30,211	(2,460)	28,598
Weighted average number of ordinary shares in issue (Unit '000)	152,786	152,786	152,786	152,786
Basic earnings per share (sen)	(3.38)	19.77	(1.61)	18.72

b. Diluted

There were no diluted earnings per share.

25. (LOSS) / PROFIT BEFORE TAX

(Loss) / profit before tax is stated after charging/(crediting):

	Individual Quarter Ended			ve Quarter ded
	30-Sep-20	30-Sep-19	30-Sep-20	30-Sep-19
	RM'000	RM'000	RM'000	RM'000
Other income	(9)	(32,011)	(50)	(32,249)
Interest income	(263)	(200)	(422)	(438)
Net foreign exchange loss/(gain)	92	51	247	109
Interest expenses	334	311	962	977



UNAUDITED NOTES TO FINANCIAL STATEMENTS

26. REALISED AND UNREALISED PROFITS/(LOSSES)

The breakdown of the retained profits of the Group as at reporting date into realised and unrealised profits/(losses) is presented as follows:

	As at 30-Sep-2020	As at 30-Sep-2019
Group's total retained profits:	RM'000	RM'000
Realised	(18,946)	22,798
Unrealised	(11,917)	342
Total Realised and unrealised	(30,863)	23,140
Less: Consol adjustments	37,655	(2,967)
Retained profits	6,792	26,107

27. AUTHORISED FOR ISSUE

The interim financial statements were authorized for issue by the Board of Directors in accordance with a resolution of the directors on 25th November 2020.

By Order of the Board Adventa Berhad CHUA SIEW CHUAN Company Secretary MAICSA 0777689